Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026
Rhea-AI Summary
Karyopharm (Nasdaq: KPTI) will report first quarter 2026 financial results on Thursday, May 14, 2026. Management will host a conference call and live audio webcast at 8:00 a.m. ET to discuss results and company updates. Slides and an archived webcast will be available on the investor website approximately two hours after the event.
Positive
- None.
Negative
- None.
News Market Reaction – KPTI
In the May 7 session, KPTI declined 1.88%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Earnings date set | Neutral | -3.3% | Scheduled Q4 and full-year 2025 results with 8:00 a.m. ET call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date scheduling news saw a modest negative reaction of -3.33%, indicating the market has treated such announcements cautiously.
Recent news for KPTI included an earnings-date announcement on Feb 05, 2026, after which the stock moved -3.33%. Other key items in 2026 were a late-breaking Phase 3 SENTRY presentation selection, a private placement with RA Capital, topline SENTRY data, equity inducement grants, and Q4/2025 earnings. Today’s first-quarter 2026 earnings-date news fits the pattern of routine scheduling updates following earlier financial and clinical disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Conference Call Scheduled for Thursday, May 14, 2026, at 8:00 a.m. ET --
To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-first-quarter-2026-financial-results-on-may-14-2026-302764337.html
SOURCE Karyopharm Therapeutics Inc.
